Country-based report: The safety of omalizumab treatment in pregnant patients with asthma
No Thumbnail Available
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants. © TÜBİTAK.
Description
Keywords
Adult , Anti-Asthmatic Agents , Antibodies, Monoclonal, Humanized , Asthma , Female , Forced Expiratory Volume , Humans , Omalizumab , Pregnancy , Pregnancy Complications , Retrospective Studies , Treatment Outcome , beta adrenergic receptor stimulating agent , corticosteroid , histamine agonist , immunoglobulin E , leukotriene receptor blocking agent , long acting drug , omalizumab , antiasthmatic agent , monoclonal antibody , omalizumab , adult , allergic rhinitis , allergy , Apgar score , Article , asthma , Asthma Control Test , atopy , birth weight , blood cell count , body mass , case study , cesarean section , clinical article , comorbidity , controlled study , demography , disease exacerbation , drug safety , drug therapy , education , employment , eosinophil count , female , first trimester pregnancy , forced expiratory volume , forced vital capacity , gestational age , hematocrit , housewife , human , immunoglobulin blood level , infant , low birth weight , obstetric delivery , occupation , outcome assessment , patient compliance , pharmacokinetics , platelet count , pregnancy , prematurity , prick test , questionnaire , retrospective study , second trimester pregnancy , smoking , spirometry , structured questionnaire , third trimester pregnancy , asthma , pregnancy , pregnancy complication , treatment outcome